期刊
CANCER INVESTIGATION
卷 33, 期 9, 页码 440-450出版社
TAYLOR & FRANCIS INC
DOI: 10.3109/07357907.2015.1064534
关键词
Soft tissue sarcomas; Trabectedin; RG7112; MDM2; Liposarcoma
类别
资金
- Institute of Health Carlos III (Ministerio de Economia y Competitividad)
- EC (European Regional Development Fund [ERDF]) [PI12/01748]
- Pharamar
MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Selected sarcoma subtypes are being treated with Trabectedin in second line, which promotes DNA damage and p53-dependent apoptosis. The aim of this study was to evaluate the improvement of Trabectedin response with MDM2 inhibitors in soft tissue sarcomas. The antitumor effects of Trabectedin, Nutlin-3A and RG7112 as single agents or in combination were examined in vitro. RG7112 significantly synergized with Trabectedin in MDM2-amplified liposarcoma cells, representing a promising new therapeutic strategy for the treatment of sarcomas with MDM2 amplification.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据